NCT06235697招募中3 期
Androgen Suppression Combined With Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Brachytherapy Boost in Patients With Unfavourable Risk Localized Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 710
- 试验地点
- 91
- 主要终点
- To compare the progression-free survival (PFS) of SBRT versus conventional EBRT plus brachytherapy boost defined as time to biochemical failure, initiation of salvage therapy, local-regional recurrence, distant progression, or death
研究概览
简要总结
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
详细描述
The usual approach for patients with unfavourable prostate cancer who are not in a study is treatment with external beam radiation therapy (EBRT) to the pelvis and prostate in combination with hormone therapy (androgen deprivation therapy - ADT). To improve control of prostate cancer at risk of returning, additional treatment with a brachytherapy boost (insertion of radiation sources directly into the prostate) is recommended. For patients who get the usual approach for this cancer, about 89 out of 100 are free of cancer after 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 9 months
- •Participants with unfavourable risk prostate cancer are eligible according to the following NCCN classification guidelines (Version 4.2022 - May 10, 2022):
- •Unfavourable-intermediate risk - has one or more of the following:
- •2 or 3 Intermediate Risk Factors (IRFs): cT2b-cT2c, Gleason 7 (grade group 2 or 3), and/or PSA 10-20 ng/ml;
- •Gleason 4+3 (grade group 3)
- •> 50% biopsy cores positive
- •High risk - has one of the following:
- •Gleason 8-10 (grade group 4 or 5)
- •PSA > 20 ng/ml
- •Very-high risk - has at least one of the following:
- •Primary Gleason pattern 5
- •2 or 3 high risk features: cT3a, Gleason 8-10 (grade group 4 or 5), and/or PSA > 20 ng/ml
- •> 4 cores with Gleason 8-10 (grade group 4 or 5)
- •ECOG performance status of 0, 1 or 2
- •Participants must be ≥ 18 years of age
- •Judged to be medically fit for brachytherapy
- •Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in either English, French or Spanish
- •Participants consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate
- •Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
- •In accordance with CCTG policy, protocol treatment is to begin within 12 weeks of participant enrollment
- •Participants must be willing to take precautions to prevent pregnancy while on study
- •ADT (LHRH agonists, antagonists, or anti-androgens) for prostate cancer is permitted for up to 30 days before study enrollment
- •5-alpha reductase inhibitors (5-ARI) are allowed, but baseline PSA will be corrected if 5-ARI use occurs within 6 months of enrollment
- •Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
- •Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- •Urinary function defined as International Prostate Symptom Score (IPSS) <
- •Alpha blockers are allowed to treat baseline urinary function
- •HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
排除标准
- •Prior pelvic radiotherapy
- •Contraindication to radical prostate radiotherapy (e.g. connective tissue disease or inflammatory bowel disease)
- •Anticoagulation medication (if unsafe to discontinue for gold seed insertion or brachytherapy implant) and/or prior or current bleeding diathesis
- •Prior steam vaporization (Rezum), transurethral resection of the prostate (TURP), prostatectomy (simple or radical), or any ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
- •Prostate volume > 60cc before start of androgen deprivation therapy
- •Anatomy that would preclude precise brachytherapy implant (such as arch interference or large median lobe)
- •Evidence of castrate resistance (defined as a rising PSA > 3.0 ng/ml while testosterone is < 3.0 nmol/l)
- •Hip prosthesis (unilateral hip replacement is allowed if dose constrains can be reasonably achieved.
研究组 & 干预措施
EBRT + Brachy Boost
Active Comparator
干预措施: Radiation (Radiation)
SBRT
Experimental
干预措施: Radiation SBRT only (Radiation)
EBRT + Brachy Boost
Active Comparator
干预措施: ADT (Drug)
结局指标
主要结局
To compare the progression-free survival (PFS) of SBRT versus conventional EBRT plus brachytherapy boost defined as time to biochemical failure, initiation of salvage therapy, local-regional recurrence, distant progression, or death
时间窗: 8.6 years
次要结局
- PSA response at 4 years compared using a Cochran-Mantel-Haenszel (CMH) test(8.6 years)
- Economic Outcomes using EQ-5D-5L(8.6 years)
- Safety and tolerability assessed by CTCAE v5.0(8.6 years)
- Overall Survival analysed using a Cox proportional hazards model and graphically described using the Kaplan-Meier method(8.6 years)
- Cause-specific Survival compared using the Gray's test(8.6 years)
- Participant-reported outcomes using EPIC-26 questionnaire(8.6 years)
- Metastasis-free Survival compared using the Gray's test(8.6 years)
- Participant-reported tolerability using PRO-CTCAE questionnaire(8.6 years)
- Economic Outcomes using FACIT-COST(8.6 years)
研究者
研究点 (91)
Loading locations...
相似试验
进行中（未招募）
2 期
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaProstate CancerNCT03436654Memorial Sloan Kettering Cancer Center102
进行中（未招募）
1 期
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate CancerProstate CancerNCT04619069Sunnybrook Health Sciences Centre60
进行中（未招募）
1 期
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerProstate CancerNCT04194554University of Michigan Rogel Cancer Center102
招募中
3 期
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsProstate CancerNCT05974774European Organisation for Research and Treatment of Cancer - EORTC1,600
进行中（未招募）
2 期
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerStage IV Prostate CancerProstate CancerNCT05189457H. Lee Moffitt Cancer Center and Research Institute32